NasdaqCM:MBOT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Microbot Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MBOT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.3%

MBOT

0.2%

US Medical Equipment

0.4%

US Market


1 Year Return

56.0%

MBOT

24.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: MBOT exceeded the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: MBOT exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

MBOTIndustryMarket
7 Day0.3%0.2%0.4%
30 Day5.7%7.4%6.1%
90 Day20.6%7.6%8.9%
1 Year56.0%56.0%25.9%24.8%20.5%17.8%
3 Year-53.6%-53.6%75.8%71.2%42.3%32.9%
5 Yearn/a143.9%124.8%84.2%63.4%

Price Volatility Vs. Market

How volatile is Microbot Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Microbot Medical undervalued compared to its fair value and its price relative to the market?

1.95x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MBOT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MBOT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MBOT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: MBOT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MBOT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MBOT is good value based on its PB Ratio (2x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Microbot Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

25.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Microbot Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Microbot Medical performed over the past 5 years?

-13.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MBOT is currently unprofitable.

Growing Profit Margin: MBOT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MBOT is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.

Accelerating Growth: Unable to compare MBOT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBOT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: MBOT has a negative Return on Equity (-27.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is Microbot Medical's financial position?


Financial Position Analysis

Short Term Liabilities: MBOT's short term assets ($28.8M) exceed its short term liabilities ($851.0K).

Long Term Liabilities: MBOT's short term assets ($28.8M) exceed its long term liabilities ($667.0K).


Debt to Equity History and Analysis

Debt Level: MBOT is debt free.

Reducing Debt: MBOT has no debt compared to 5 years ago when its debt to equity ratio was 53.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBOT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MBOT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 40.4% each year


Next Steps

Dividend

What is Microbot Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MBOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MBOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MBOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MBOT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MBOT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Harel Gadot (47 yo)

3.92yrs

Tenure

US$1,000,293

Compensation

Mr. Harel Gadot is the Founder of MEDX Ventures Group LLC and serves as its Chairman. Mr. Gadot has been the Chief Executive Officer and President of Microbot Medical Inc. since November 28, 2016 and its C ...


CEO Compensation Analysis

Compensation vs Market: Harel's total compensation ($USD1.00M) is above average for companies of similar size in the US market ($USD578.04K).

Compensation vs Earnings: Harel's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Harel Gadot
Co-Founder3.92yrsUS$1.00mno data
David Naim
Chief Financial Officer3.92yrsUS$94.58k0%
$ 0
Moshe Shoham
Co-Founderno dataUS$33.65kno data
Simon Sharon
CTO & Chairman of Scientific Advisory Boardno datano datano data
Eric Leuthardt
Scientific Director & Member of Scientific Advisory Boardno datano datano data
Eyal Morag
Chief Medical Officer & Member of Scientific Advisory Board2.92yrsno datano data

3.9yrs

Average Tenure

53yo

Average Age

Experienced Management: MBOT's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Harel Gadot
Co-Founder3.92yrsUS$1.00mno data
Moshe Shoham
Co-Founderno dataUS$33.65kno data
Simon Sharon
CTO & Chairman of Scientific Advisory Boardno datano datano data
Eric Leuthardt
Scientific Director & Member of Scientific Advisory Boardno datano datano data
Eyal Morag
Chief Medical Officer & Member of Scientific Advisory Board2.92yrsno datano data
Scott Burell
Independent Director3.92yrsUS$64.82k0%
$ 0
Tal Wenderow
Independent Director0.25yrno datano data
Yoseph Bornstein
Co-Founder & Independent Director3.92yrsUS$64.97k0%
$ 0
Martin Madden
Independent Director3.67yrsUS$63.47k0%
$ 0
Prattipati Laxminarain
Independent Director2.83yrsUS$50.97k0%
$ 0
Aileen Stockburger
Independent Director0.50yrno datano data

3.3yrs

Average Tenure

57yo

Average Age

Experienced Board: MBOT's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 64.9%.


Top Shareholders

Company Information

Microbot Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Microbot Medical Inc.
  • Ticker: MBOT
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$55.405m
  • Shares outstanding: 7.10m
  • Website: https://www.microbotmedical.com

Number of Employees


Location

  • Microbot Medical Inc.
  • 25 Recreation Park Drive
  • Unit 108
  • Hingham
  • Massachusetts
  • 2043
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CY9DDB (Deutsche Boerse AG)YesNew Common StockDEEURNov 2016
MBOTNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDNov 2016

Biography

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, thr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:31
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.